Effects of Yangxue Qingnao Granules on chronic cerebral circulation
insufficiency: a randomized, double-blind, double-dummy, controlled multicentre
trial.
Author(s): Wu C(1), Liao L, Yan X, Li M, Wu S, Wang J, Lin J, Li S, Gao L, DU J, Yang R;
Yangxue Qingnao Granule CHRONIC CEREBRAL HYPOPERFUSION STUDY GROUP.
Affiliation(s): Author information:
(1)Department of Neurology, Second Affiliated Clinical College of Fujian University
of Traditional Chinese Medicine, China.
Publication date & source: 2013, Psychogeriatrics. , 13(1):29-34
BACKGROUND: There is a great deal of interest in traditional Chinese medicine as
a treatment for chronic cerebral circulation insufficiency (CCCI). In the present
study, we evaluated the efficacy and safety of Yangxue Qingnao Granules (YXQNG)
as a monotherapy in patients with CCCI.
METHODS: From July 2007 to May 2010, 273 patients with CCCI at nine centres in
China were randomly assigned to receive either YXQNG with nimodipine placebo (n=
140, 12 g/day) or nimodipine with YXQNG placebo (n= 133, 30 mg/day) for 8 weeks.
The primary end points after 8 weeks of treatment were changes from baseline in
severity of headache, heavy-headed feeling, dizziness and sleep disorder.
RESULTS: The mean baseline levels of headache, heavy-headed feeling, dizziness
and sleep disorder were comparable between the two groups. Both therapies
significantly improved these symptoms after 8 weeks of treatment (P < 0.001).
Compared with nimodipine therapy, YXQNG resulted in similar reductions in these
symptoms. No adverse effects were observed in the YXQNG group.
CONCLUSIONS: These data demonstrate that YXQNG as a monotherapy were as effective
as nimodipine monotherapy in improving the symptoms of CCCI. It is well-tolerated
and may have an important place in the management of this condition. Whether a
combination of these two medicines will increase therapeutic efficacy deserves
further clinical investigation.
|